Antinuclear antibodies in patients taking L1
- 16 March 1991
- journal article
- other
- Published by Elsevier in The Lancet
- Vol. 337 (8742) , 672
- https://doi.org/10.1016/0140-6736(91)92483-i
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia majorBritish Journal of Haematology, 1990
- Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patientsThe Lancet, 1990
- Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIESBritish Journal of Haematology, 1990
- Sudden death after treatment with pulsed methylprednisolone.BMJ, 1990
- Severe Cardiovascular Adverse Effects in Association with Acute, High-Dose Corticosteroid AdministrationDICP, 1989
- 11 The toxic effects of desferrioxamineBailliere's Clinical Haematology, 1989
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985